← Back
NeuroTrials.ai
Neurology Clinical Trial Database

DSE-Migraine-MA

Digital screen exposure and migraine burden: a systematic review and meta-analysis

Year of Publication: 2026

Authors: Gowda N, Harish S, Tej G

Journal: Journal of Neurology

Citation: J Neurol 2026;273:525. DOI: 10.1007/s00415-026-14062-y

Link: https://doi.org/10.1007/s00415-026-14062-y


Clinical Question

Is higher digital screen exposure associated with greater migraine or headache burden (risk, frequency, severity, disability) in adolescents and adults?

Bottom Line

In a random-effects meta-analysis of 10 studies (N=11,218), higher digital screen exposure was associated with a ~60% greater odds of migraine or headache (pooled OR 1.60, 95% CI 1.38–1.86, p<0.001), with directionally consistent adult and paediatric subgroup effects and robustness to leave-one-out. Overall certainty of evidence was low (GRADE), reflecting cross-sectional exposure ascertainment, residual confounding, and possible small-study effects; screen exposure should be regarded as a modifiable factor to assess in migraine care, pending prospective and interventional confirmation.

Major Points

  • 22 studies (N=14,763) met eligibility criteria; 10 studies (N=11,218) with OR data were pooled by random-effects (DerSimonian–Laird) meta-analysis.
  • Primary result: higher vs lower screen exposure — pooled OR 1.60 (95% CI 1.38–1.86, p<0.001); heterogeneity I2=60%, Cochran Q=22.3, df=9, p=0.008; 95% prediction interval 1.03–2.48.
  • Adult subgroup pooled OR 1.87 (95% CI 1.43–2.44); paediatric/adolescent subgroup OR 1.46 (95% CI 1.24–1.72) — direction consistent across age groups.
  • Leave-one-out sensitivity analysis: pooled OR ranged 1.52–1.67, indicating no single study drove the pooled estimate.
  • Egger's regression suggested small-study effects (intercept 3.71, p=0.002); certainty of evidence rated LOW (GRADE).
  • Two clinic-based comparative studies found no significant difference in headache frequency or severity by smartphone-use status — the only null narrative signals.
  • Consistent secondary associations across the full 22-study set: sleep disturbance 18/22, reduced quality of life 20/22, visual/ocular discomfort 14/22, psychiatric comorbidity 13/22, musculoskeletal symptoms 11/22.
  • Mechanistic convergence across included studies: blue light–mediated retinal ganglion cell activation, melatonin suppression / circadian disruption, and trigeminovascular / cortical hyperexcitability.

Design

Study Type: Systematic review and random-effects meta-analysis (DerSimonian–Laird) of observational (predominantly cross-sectional) and interventional studies

Randomization:

Blinding: Not applicable (dual independent screening, extraction, and risk-of-bias assessment)

Enrollment Period: No date restriction on included studies (published searches conducted for this review; database search dates as reported by authors)

Follow-up Duration: Not applicable (cross-sectional and observational data)

Centers: 0

Countries: multinational (studies from India, Egypt, Saudi Arabia, Bangladesh, Brazil, Turkey, France, Serbia, Denmark, Philippines, Germany, Italy, USA and others)

Sample Size: 14763

Analysis: PRISMA 2020–compliant; PROSPERO-registered (CRD420261404162). Databases searched: Embase, MEDLINE, PubMed, Scopus, Google Scholar. Two reviewers independently screened, extracted data, and assessed risk of bias using a modified Joanna Briggs Institute (JBI)/AHRQ checklist for cross-sectional and observational studies. Pooling threshold: ≥10 studies reporting OR with 95% CI for higher vs lower screen exposure — random-effects (DerSimonian–Laird) meta-analysis. Heterogeneity by I2 and Cochran's Q; small-study effects by Egger's regression; robustness by leave-one-out. Outcomes not amenable to pooling synthesised narratively. Certainty of evidence rated using GRADE.


Inclusion Criteria

  • Observational (cross-sectional, case-control, cohort) or interventional studies
  • Adolescent or adult participants with migraine or primary headache
  • Quantifiable measure of digital screen exposure (screen time or device use)
  • Reported migraine/headache outcomes (frequency, severity, disability) or secondary outcomes (sleep, quality of life, visual/ocular, psychiatric, musculoskeletal)
  • English-language publication
  • No date restriction on publication year

Exclusion Criteria

  • Non-English publications
  • Studies without a quantifiable screen-exposure measure
  • Studies not reporting headache or migraine outcomes
  • Case reports, narrative reviews, editorials, and conference abstracts without full data
  • Duplicate publications

Baseline Characteristics

CharacteristicPooled meta-analysis subset (n=10 studies, N=11,218)Full narrative synthesis set (n=22 studies, N=14,763)
Study designsPredominantly cross-sectional observational studies22 studies — mix of cross-sectional, correlational, comparative clinic-based studies
PopulationsMix of paediatric/adolescent and adult cohorts (community, school, university, and clinic samples)
Exposure ascertainmentSelf-reported screen time (hours/day) or device-use categorisations
Outcome ascertainmentSelf-reported migraine/headache; some studies used ICHD criteria
Effect measureOdds ratio (higher vs lower screen exposure) with 95% CI
Age rangeAdolescents through adults
Geographic distributionMultinational: India, Egypt, Saudi Arabia, Bangladesh, Brazil, Turkey, France, Serbia, Denmark, Philippines, Germany, Italy, USA and other countries as represented in the included references
Outcome domains reportedHeadache/migraine risk, frequency, severity, disability; sleep disturbance; QOL; visual/ocular symptoms; psychiatric comorbidity; musculoskeletal symptoms

Arms

FieldHigher screen exposureControl
InterventionHigher digital screen time / heavier device use (as dichotomised or top-category within each study)Lower digital screen time / lighter device use (reference category within each study)
N00

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Pooled odds of migraine or headache with higher vs lower digital screen exposure (random-effects DerSimonian–Laird meta-analysis of 10 studies, N=11,218)PrimaryLower screen exposure (reference)Higher screen exposure — pooled OR 1.601.6<0.001
Adult subgroup pooled OR (higher vs lower screen exposure)SecondaryAdults with lower screen exposureAdults with higher screen exposure1.87
Paediatric / adolescent subgroup pooled OR (higher vs lower screen exposure)SecondaryPaediatric/adolescent with lower screen exposurePaediatric/adolescent with higher screen exposure1.46
Sleep disturbance associated with screen exposure (narrative synthesis)Secondary-Reported in 18/22 studies (82%)
Reduced quality of life associated with screen exposure (narrative synthesis)Secondary-Reported in 20/22 studies (91%)
Visual / ocular discomfort associated with screen exposure (narrative synthesis)Secondary-Reported in 14/22 studies (64%)
Psychiatric comorbidity associated with screen exposure (narrative synthesis)Secondary-Reported in 13/22 studies (59%)
Musculoskeletal symptoms associated with screen exposure (narrative synthesis)Secondary-Reported in 11/22 studies (50%)
Two clinic-based comparative studies — headache frequency or severity by smartphone-use statusSecondaryNo significant differenceNo significant differencens
Not applicable — observational meta-analysis of exposure/outcome associations; no interventional adverse events reported.Safety--

Subgroup Analysis

Prespecified age-based subgroups showed directionally consistent effects: adults OR 1.87 (1.43–2.44); paediatric/adolescent OR 1.46 (1.24–1.72). Leave-one-out sensitivity analysis: pooled OR range 1.52–1.67 across sequential exclusion of each of the 10 pooled studies, confirming robustness.


Criticisms

  • Almost all included studies were cross-sectional — cannot establish temporality or causality between screen exposure and migraine/headache.
  • Screen exposure was self-reported and often heterogeneously categorised across studies, introducing exposure-measurement error.
  • Moderate statistical heterogeneity (I2=60%) and a wide 95% prediction interval (1.03–2.48) indicate the underlying true effect could plausibly be small in some populations.
  • Egger's test intercept 3.71 (p=0.002) suggests small-study effects and possible publication bias — smaller studies with larger reported effects are over-represented.
  • Residual confounding (sleep quality, mental health, socioeconomic status, concurrent digital-media content) was inconsistently addressed across included studies.
  • Two clinic-based comparative studies were null, contrasting with the pooled positive effect — highlighting setting-specific confounding.
  • Language restriction to English may have excluded relevant regional evidence.
  • GRADE overall certainty of evidence for the primary outcome was rated LOW, reflecting these limitations.
  • Narrative outcomes (sleep, QOL, visual, psychiatric, musculoskeletal) were tallied qualitatively; the review did not pool these secondary outcomes quantitatively.

Funding

No funding was received for the conduct of this study.

Based on: DSE-Migraine-MA (Journal of Neurology, 2026)

Authors: Gowda N, Harish S, Tej G

Citation: J Neurol 2026;273:525. DOI: 10.1007/s00415-026-14062-y

Content summarized and formatted by NeuroTrials.ai.